HAYWARD, Calif., July 11, 2011 /PRNewswire/ — Molecular
diagnostics company GenturaDx announced today that Geoffrey A.
McKinley, Ph.D., has joined the company as Senior Vice President of
Research & Development. McKinley joins as GenturaDx
accelerates research to bring its IDbox™ System to
commercialization.
(Photo: http://photos.prnewswire.com/prnh/20110711/LA32940)
“With his depth of experience developing molecular diagnostic
products, Geoff will be a key asset in commercializing our
molecular platform in the next 12 to 24 months,” said Mark Bagnall,
GenturaDx’s chief executive officer. “GenturaDx anticipates
completing beta studies this year and clinical studies in 2012, and
Geoff is an important addition to a talented R & D team working
to perfect our system as well as develop partnerships with
companies that seek to adapt assay content to our platform.”
Dr. McKinley brings to GenturaDx nearly two decades of research
& development and business development experience related to
developing molecular diagnostic products and tools for infectious
diseases. Prior to joining GenturaDx, Dr. McKinley was
responsible for research & development to support molecular
biology assay, consumable and instrumentation development at
Osmetech, Inc. He has previously held positions at Naxcor, Inc.,
BioMerieux, Inc., and Analytab Products, a division of Sherwood
Medical. Dr. McKinley earned his Ph.D. at Colorado State
University.
“It’s a great time to be at GenturaDx,” Dr. McKinley said,
“because its unique, PCR-based, sample-to-answer IDbox System has
the potential to dramatically impact molecular diagnostics,
offering potential performance advantages over existing systems on
the market and making the molecular testing affordable and easy to
use for the estimated 5,000 small-to-medium sized hospitals that
rely on traditional culture techniques or
‘/>”/>
